Confirmation of the possibility of treating Parkinson’s disease with adipose-derived stem cells

• Joint research led by Suh Yoo-hun, the President of the Korea Brain Research Institute, Dr. Jang Geun-ah, a Professor at the Gachon University School of Medicine, and Ra Jeong-chan, the President of the Biostar Stem Cell Research Institute
• Results published in an international journal called Neurobiology of Aging (Impact Factor 5.013) (Accepted on June 15)
• Nature Cell, planning to conduct a commercial clinical trial

It has been confirmed that adipose-derived adult stem cells can be cultured and used to treat Parkinson’s disease, an intractable disease for which an ideal therapeutic method has not yet been developed.

Joint research led by Suh Yoo-hun, the President of the Korea Brain Research Institute, and Dr. Jang Geun-ah, Professor at the Gachon University School of Medicine was conducted together with the research team headed by Dr. Ra Jeong-chan, the President of the Biostar Stem Cell Research Institute. The findings showed a possibility of treating Parkinson’s disease-induced animals with intravenous injections of stem cells, and these results were published in international scientific journal called Neurobiology of Aging (IF 5.013).

The results showed that the adipose-derived stem cells cultured by the Biostar Stem Cell Research Institute helped improve the motor ability of the animal models of Parkinson’s disease through intravenous injections. The study also led to the discovery of the fact that adipose-derived stem cells can prevent the death of dopamine-producing nerve cells and the damage and destruction of mitochrondria in substantia nigra lesion in the brain, and activate Mitochondria Complex I, a primary enzyme in the mitochondrial respiratory chain.

This confirmed the possibility of treating Parkinson’s disease with adipose-derived stem cells and the mechanism of action, and research for commercialization of the technology in question will be conducted at an accelerated rate.

Meanwhile, Nature Cell Co., Ltd. plans to conduct a commercial clinical trial with Parkinson’s disease patients, in collaboration with Biostar.